Published in Genetics and Environmental Business Week, January 25th, 2007
The pharmaceutical company will make payments totaling US$1.01 million (AUD 1.3 million) to pSivida for the right to exclusively negotiate a licensing agreement with the company for a period of 3 months and to fund the cost of a preclinical study. The preclinical study will focus on an evaluation of pSivida's drug delivery technologies in a very significant product opportunity.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.